WO2013155528A3 - Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels - Google Patents
Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels Download PDFInfo
- Publication number
- WO2013155528A3 WO2013155528A3 PCT/US2013/036639 US2013036639W WO2013155528A3 WO 2013155528 A3 WO2013155528 A3 WO 2013155528A3 US 2013036639 W US2013036639 W US 2013036639W WO 2013155528 A3 WO2013155528 A3 WO 2013155528A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- reducing
- formula
- methods
- insulin sensitivity
- increasing insulin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels in a subject including by administering one or more compounds of Formula I, Formula II, or both are provided. The present disclosure provides for, and includes the use of a compound of Formula I, Formula II, or both for the manufacture of a medicine for reducing inflammation. In certain aspects, the compound of Formula I is FSG67 and the compound of Formula II is C75. The present disclosure also provides for, and includes, the use of a compound of Formula I, Formula II, or both for the manufacture of a medicine for the activation of palmitate oxidation in a subject in need.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261623896P | 2012-04-13 | 2012-04-13 | |
US61/623,896 | 2012-04-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013155528A2 WO2013155528A2 (en) | 2013-10-17 |
WO2013155528A3 true WO2013155528A3 (en) | 2013-12-05 |
Family
ID=49328292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/036639 WO2013155528A2 (en) | 2012-04-13 | 2013-04-15 | Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2013155528A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160231334A1 (en) * | 2013-10-28 | 2016-08-11 | The Forsyth Institute | Compositions and Methods for Evaluating Metabolic Syndrome and Related Diseases |
PE20160901A1 (en) | 2013-12-18 | 2016-08-27 | Astex Therapeutics Ltd | NRF2 REGULATORS |
KR101705253B1 (en) * | 2014-10-06 | 2017-02-22 | 울산과학기술원 | Pharmaceutical composition for prevention or treatment of inflammatory diseases comprising cerulenin or cerulenin derivative as an active ingredient |
EP3220901B1 (en) | 2014-11-20 | 2020-02-19 | VIB vzw | Means and methods for treatment of early-onset parkinson's disease |
WO2016202253A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
KR20180018684A (en) | 2015-06-15 | 2018-02-21 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | NRF2 modulator |
EP3359532A1 (en) | 2015-10-06 | 2018-08-15 | GlaxoSmithKline Intellectual Property Development Limited | Biaryl pyrazoles as nrf2 regulators |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040033506A1 (en) * | 2001-11-30 | 2004-02-19 | Dennis Farrelly | Polynucleotides encoding novel human mitochondrial and microsomal glycerol-3-phosphate acyl-transferases and variants thereof |
US20050106217A1 (en) * | 2002-02-08 | 2005-05-19 | Johns Hopkins University Licensing And Technology Development | Stimulation of CPT-1 as a means to reduce weight |
US20110274654A1 (en) * | 2010-05-05 | 2011-11-10 | Bahadoor Adilah | Triazoles as inhibitors of fatty acid synthase |
US20120083471A1 (en) * | 2008-07-07 | 2012-04-05 | Townsend Craig A | Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same |
-
2013
- 2013-04-15 WO PCT/US2013/036639 patent/WO2013155528A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040033506A1 (en) * | 2001-11-30 | 2004-02-19 | Dennis Farrelly | Polynucleotides encoding novel human mitochondrial and microsomal glycerol-3-phosphate acyl-transferases and variants thereof |
US20050106217A1 (en) * | 2002-02-08 | 2005-05-19 | Johns Hopkins University Licensing And Technology Development | Stimulation of CPT-1 as a means to reduce weight |
US20120083471A1 (en) * | 2008-07-07 | 2012-04-05 | Townsend Craig A | Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same |
US20110274654A1 (en) * | 2010-05-05 | 2011-11-10 | Bahadoor Adilah | Triazoles as inhibitors of fatty acid synthase |
Also Published As
Publication number | Publication date |
---|---|
WO2013155528A2 (en) | 2013-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013155528A3 (en) | Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels | |
HK1214168A1 (en) | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level | |
JP2012107034A5 (en) | ||
EP3682875A3 (en) | Methods of treating pediatric metabolic syndrome | |
WO2013170068A3 (en) | Nuclear transport modulators and uses thereof | |
BR112014031806A8 (en) | gd2 positive cancer treatment method | |
WO2014205389A8 (en) | Nuclear transport modulators and uses thereof | |
MX2015002669A (en) | Methods of administering pirfenidone therapy. | |
WO2012149299A3 (en) | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor | |
NZ727304A (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
MX356728B (en) | Pharmaceutical combination for use in the treatment of diabetes type 2. | |
UA113849C2 (en) | THE APPLICATION OF SIGMA LIGANDS IN TYPE 2 PATIENTS WITH PAIN | |
WO2013028818A8 (en) | Pyrimido- pyridazinone compounds and use thereof | |
MX2013011124A (en) | Compounds for treatment of metabolic syndrome. | |
MX2015011359A (en) | Macrocyclic lrrk2 kinase inhibitors. | |
WO2014160281A3 (en) | Method of enhancing delivery of therapeutic compounds to the eye | |
PH12014502071A1 (en) | Beta-hydroxy-beta-methylbutyric acid for imrpoving glucose tolerance | |
EP3013219A4 (en) | Low glucose treatment for people with diabetes | |
MX2014014814A (en) | Pharmaceutical composition for treating inflammation and pain. | |
BR112014032169A2 (en) | therapeutic treatments with anti-her2 antibodies having low fucosylation | |
WO2013090319A3 (en) | Treatment of type i and type ii diabetes | |
WO2013111013A8 (en) | Methods for treating alzheimer's disease by administering certain synthetic compounds | |
WO2011161295A3 (en) | Use of anticalcineurin compounds for the treatment of pathologies involving ocular neovascularisation | |
WO2012145234A3 (en) | Cyclopropyl derivatives and methods of use | |
WO2014147578A3 (en) | Antibacterial compounds against drug resistant bacteria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13775534 Country of ref document: EP Kind code of ref document: A2 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 26/03/2015) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 13775534 Country of ref document: EP Kind code of ref document: A2 |